Issue 5, 2010

Anticancer mechanism of peptide P18 in human leukemia K562 cells

Abstract

Studies on the anticancer mechanism of peptide P18 in human leukemia K562 cells revealed that P18 causes the death of most K562 cells by depolarizing plasma membrane potential and enhancing membrane permeability, rather than activating the classical apoptosis pathway. The mechanistic studies indicate that disrupting plasma membrane is an effective approach to kill cancer cells and help design more effective peptide analogues in future cancer therapies.

Graphical abstract: Anticancer mechanism of peptide P18 in human leukemia K562 cells

Article information

Article type
Communication
Submitted
05 Oct 2009
Accepted
11 Dec 2009
First published
07 Jan 2010

Org. Biomol. Chem., 2010,8, 984-987

Anticancer mechanism of peptide P18 in human leukemia K562 cells

C. Tang, X. Shao, B. Sun, W. Huang, F. Qiu, Y. Chen, Y. Shi, E. Zhang, C. Wang and X. Zhao, Org. Biomol. Chem., 2010, 8, 984 DOI: 10.1039/B920762G

To request permission to reproduce material from this article, please go to the Copyright Clearance Center request page.

If you are an author contributing to an RSC publication, you do not need to request permission provided correct acknowledgement is given.

If you are the author of this article, you do not need to request permission to reproduce figures and diagrams provided correct acknowledgement is given. If you want to reproduce the whole article in a third-party publication (excluding your thesis/dissertation for which permission is not required) please go to the Copyright Clearance Center request page.

Read more about how to correctly acknowledge RSC content.

Social activity

Spotlight

Advertisements